DeepMed Research

Nanfang Hospital Southern Medical University

🇨🇳China

Country: 🇨🇳China

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Prospective Study on the Efficacy and Safety of Bronchoalveolar Lavage Combined With Pathogen Metagenomic Sequencing Technology in the Diagnosis of Immune Checkpoint Inhibitor Associated Pneumonia

Recruiting

Conditions: Immune Checkpoint Inhibitor Associated Pneumonia

Interventions: Diagnostic Test: Bronchoalveolar lavage and pathogen metagenomic sequencing

First Posted Date: 2024-01-05

Last Posted Date: 2024-01-05

Lead Sponsor: Nanfang Hospital, Southern Medical University

Target Recruit Count: 104

Registration Number: NCT06192303

Locations: 🇨🇳
Southern Medical University Nanfang Hospital, Guangzhou, Guangdong, China

The Diagnostic Value of APTT/Fibrinogen Ratio in Pulmonary Embolism

Recruiting

Conditions: Acute Pulmonary Embolism

Interventions: Diagnostic Test: 2018 edition of the Guidelines for Diagnosis

First Posted Date: 2024-01-05

Last Posted Date: 2025-04-16

Lead Sponsor: Nanfang Hospital, Southern Medical University

Target Recruit Count: 800

Registration Number: NCT06192199

Locations: 🇨🇳
Nanfang hospital of Southern Medical University, Guangzhou, Guangdong, China

Population-wide Research for HBV-related Liver Diseases in Maoming City

Not yet recruiting

Conditions: Chronic Hepatitis B
HBV Infection
HCC
Cirrhosis

Interventions: Other: Rapid tests for HBsAg

First Posted Date: 2023-12-28

Last Posted Date: 2024-01-09

Lead Sponsor: Nanfang Hospital, Southern Medical University

Target Recruit Count: 3700000

Registration Number: NCT06184347

A Phase Ⅱ Clinical Study of Adebrelimab Combined With Chemotherapy and Concurrent Radiotherapy for Extensive-Stage Oligometastatic SCLC

Phase 2

Recruiting

Conditions: Respiratory Tract Neoplasms
Thoracic Neoplasms
Neoplasms by Site
Neoplasms
Lung Diseases
Respiratory Tract Diseases
Small Cell Lung Carcinoma
Carcinoma, Bronchogenic
Bronchial Neoplasms
Lung Neoplasms

Interventions: Drug: Adebrelimab
Drug: Carboplatin/Cisplatin
Drug: Etoposide
Radiation: Radiation therapy

First Posted Date: 2023-12-20

Last Posted Date: 2023-12-20

Lead Sponsor: Nanfang Hospital, Southern Medical University

Target Recruit Count: 62

Registration Number: NCT06177925

Locations: 🇨🇳
Nanfang Hospital, Southern Medical University, Guangzhou, China

Diaphragm Dysfunction After COVID-19 as Determined by Dynamic Chest Radiography

Recruiting

Conditions: Long Covid19

Interventions: Device: dynamic chest radiography

First Posted Date: 2023-12-19

Last Posted Date: 2023-12-26

Lead Sponsor: Nanfang Hospital, Southern Medical University

Target Recruit Count: 24

Registration Number: NCT06175455

Locations: 🇨🇳
Yudong, Guangzhou, Guangdong, China

SSM Predicts Outcomes of CLD Inpatients With Acute Liver Injury

Recruiting

Conditions: Jaundice
End Stage Liver Disease
Portal Hypertension
Liver Dysfunction

First Posted Date: 2023-12-18

Last Posted Date: 2025-05-21

Lead Sponsor: Nanfang Hospital, Southern Medical University

Target Recruit Count: 411

Registration Number: NCT06173947

Locations: 🇨🇳
Hepatology Unit, Department of Infectious Diseases, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China

A Bidirectional Cohort Study of COMMD10 Expression in Tumor Tissues for Predicting Radiosensitivity

Recruiting

Conditions: Radiosensitivity
Biomarker

First Posted Date: 2023-12-11

Last Posted Date: 2024-03-15

Lead Sponsor: Nanfang Hospital, Southern Medical University

Target Recruit Count: 400

Registration Number: NCT06165224

Locations: 🇨🇳
Nanfang hospital, Southern medical university, Guangzhou, Guangdong, China

Lenvatinib Plus Tislelizumab and CapeOX as First-Line Treatment for Advanced GC/GEJC With Positive PD-L1 and Low TMEscore

Phase 2

Recruiting

Conditions: Gastric Cancer

Interventions: Drug: lenvatinib and tislelizumab plus CapeOX chemotherapy
Drug: tislelizumab plus CapeOX chemotherapy

First Posted Date: 2023-12-06

Last Posted Date: 2023-12-06

Lead Sponsor: Nanfang Hospital, Southern Medical University

Target Recruit Count: 92

Registration Number: NCT06157996

Locations: 🇨🇳
Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China

Post-transplant PT/FLU+CY Promotes Unrelated Cord Blood Engraftment in Haplo-cord Setting in Childhood Leukemia

Not Applicable

Recruiting

Conditions: Stem Cell Transplant
Cord Blood
Leukemia

Interventions: Procedure: applying of FLU+CY post-HSCT

First Posted Date: 2023-12-04

Last Posted Date: 2023-12-04

Lead Sponsor: Nanfang Hospital, Southern Medical University

Target Recruit Count: 60

Registration Number: NCT06155188

Locations: 🇨🇳
Nanfang Hospital, Guangzhou, Guangdong, China

Pirfenidone as a Radiosensitizer in the Treatment of Head and Neck Squamous Cell Carcinoma

Phase 2

Recruiting

Conditions: Radiosensitizer
Head and Neck Squamous Cell Carcinoma
Radiotherapy
Pirfenidone

Interventions: Drug: Placebo
Drug: Pirfenidone

First Posted Date: 2023-11-21

Last Posted Date: 2023-11-21

Lead Sponsor: Nanfang Hospital, Southern Medical University

Target Recruit Count: 66

Registration Number: NCT06142318

Locations: 🇨🇳
Fujian Provinical Hospital, Fuzhou, China
🇨🇳
Jieyang people's hospital, Jieyang, China
🇨🇳
Huizhou Central People's Hospital, Huizhou, China

and more 2 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy